**Review Article**

Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches

Sachiko Ozawa,1,2* Colleen R. Higgins,1 Jude I. Nwokike,3 and Souly Phanouvong4

1Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina; 2Department of Maternal and Child Health, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina; 3Promoting the Quality of Medicines Plus (PQM +) Program, U.S. Pharmacopeial Convention, Rockville, Maryland

**Abstract.** Substandard and falsified medicines are harmful to patients, causing prolonged illness, side effects, and preventable deaths. Moreover, they have an impact on the health system and society more broadly by leading to additional care, higher disease burden, productivity losses and loss of trust in health care. Models that estimate the health and economic impacts of substandard and falsified medicines can be useful for regulators to contextualize the problem and to make an economic case for solutions. Yet these models have not been systematically catalogued to date. We reviewed existing models that estimate the health and economic impact of substandard and falsified medicines to describe the varying modeling approaches and gaps in knowledge. We compared model characteristics, data sources, assumptions, and limitations. Seven models were identified. The models assessed the impact of antimalarial (n = 5) or antibiotic (n = 2) quality at a national (n = 4), regional (n = 2), or global (n = 1) level. Most models conducted uncertainty analysis and provided ranges around potential outcomes. We found that models are lacking for other medicines, few countries’ data have been analyzed, and capturing population heterogeneity remains a challenge. Providing the best estimates of the impact of substandard and falsified medicines on a level that is actionable for decision-makers is important.

To enable this, research on the impact of substandard and falsified medicines should be expanded to more medicine types and classes and tailored to more countries that are affected, with greater specificity.

**INTRODUCTION**

Approximately one in 10 essential medicines in low- and middle-income countries (LMICs) have been found to fail quality testing.1,2 The WHO defines these medicines as "substandard" when they do not meet their quality standards and/or specifications or "falsified" when they are intentionally made to misrepresent their identity, composition, or source.3 Patients who use substandard and falsified medicines can experience prolonged illness due to lack of or reduced effective active pharmaceutical ingredient, adverse effects due to toxic ingredients, and financial harm from having to pay for additional health care or needing to take time away from work. Yet such harm caused by substandard and falsified medicines is not fully understood, and the true impact on the population, health system, and economy is often unknown. As more data on the prevalence of substandard and falsified medicines are collected, efforts to estimate their health and economic consequences has become possible through decision-modeling. The results of these models can aid national medicines regulatory authorities (NMRAs) and health ministries to contextualize the issue alongside other public health investments and prioritize interventions that have a high return. This review compiles models used to estimate the health or economic burden attributable to substandard and falsified medicines to compare the mechanisms used for these estimations and to uncover gaps in knowledge within this field.

We provide a narrative overview of the literature comparing different modeling methods and synthesizing the findings. A search was performed in February 2021 in PubMed and Scopus to identify models that estimate the health and/or economic impact of substandard and falsified medicines. Search terms used were “substandard” or “falsified” and “medicines,” along with “model” or “impact.” Google was used to search for gray literature using the same search terms. Articles or standalone models were included if they used modeling techniques to predict or estimate the effects of substandard and/or falsified medicines across a population. Models that were already known to the authors were added to search results. We compared model approaches and characteristics, data sources, assumptions, and limitations.

**MODELS EXAMINING SUBSTANDARD AND FALSIFIED MEDICINES**

Database searches resulted in 642 articles screened, including 375 articles in PubMed and 267 articles in Scopus. After screening each article, we identified seven models that fit our inclusion criteria. This included four models that estimated the burden of substandard and falsified medicines, two models that examined the cost-effectiveness of medicine quality screening technologies, and one model that examined the impact of poor-quality medicines on development of antimicrobial resistance. The seven models assessed the impact of poor-quality antimalarials (n = 5) or antibiotics (n = 2) and focused on estimating the impact at the national (n = 4), regional (n = 2), or global (n = 1) levels. Included were three decision tree models, two agent-based models, one statistical model, and one transmission dynamics model. Most models conducted uncertainty analysis and provided ranges around potential outcomes. Table 1 synthesizes the characteristics of each model.

Modeling the burden of substandard and falsified medicines. The only global estimate came from a decision-tree model developed by the University of Edinburgh and the...
### Table 1

**Characteristics of Models**

| Purpose | Scope | Medicine and population | Structure | Mechanism for modeling SF impact on patients | Main inputs & data sources |
|---------|-------|--------------------------|-----------|---------------------------------------------|---------------------------|
| Provided rough estimates of increased mortality of childhood pneumonia due to use of SF medicines | Global: broken into industrialized and developing countries | Antibiotics used for pediatric ALRI/pneumonia | Decision tree | Twice the case fatality rate was applied for children using SF medicines | Deaths, severe cases, case fatality rate: previous modeling analysis specific to pediatric respiratory infection |
| Modeled the health and economic cost of SF drugs for first-line treatment of uncomplicated *Plasmodium falciparum* malaria in sub-Saharan Africa | Regional: sub-Saharan Africa | Antimalarials: ACTs and non-ACTs used for malaria, all ages | Decision tree | SF medicines resulted in reduced effectiveness | Care-seeking: published literature, combined for all countries |
| Modeled the health impact of poor-quality antimalarials on SP-resistant malaria infections | National: Kenya | Antimalarials: SP and ACTs used for malaria, all ages | Transmission dynamics model, with host and vector models | SF antimalarials increased probability of severe disease and increased probability that severe cases result in death | Medicines received: DHS, SF Prevalence: published literature, generalized to Kenya |
| Estimated the cost-effectiveness of portable screening devices and 5-year budget impact of implementing them | National: Laos | Antimalarials: ACTs used for all ages | Decision tree | SF medicines resulted in reduced effectiveness | Incidence/cases: WHO Performance of the devices: laboratory experiments |
| Estimated the health and economic burden caused by SF antimalarials | National: Benin, DRC, Uganda, Nigeria, Zambia | Antimalarials: ACTs, chloroquine, quinine, monotherapy, used for pediatric malaria | Agent-based model in which medicines are the agents | SF antimalarials increased probability of severe disease and increased probability that severe cases result in death | Costs: device costs from manufacturers, |
| Modeled SF prevalence on the market and the health and economic impact of quickly screening then removing SF amoxicillin before being used by patients | National: Kenya Regional: sub-Saharan Africa | Antibiotics: Amoxicillin used for pediatric pneumonia | Statistical | SF medicines resulted in reduced effectiveness | Incidence/cases: World Malaria Report |
| Estimated the number of under-5 malaria deaths attributable to poor-quality antimalarials | Regional: sub-Saharan Africa | Antimalarials: ACTs, SP used for pediatric malaria | Increase in case fatality rate was applied for taking SF antimalarials | Scenario implementing screening technology to quickly remove SF amoxicillin from the market was compared with scenarios where SF medicines were left on the market longer and used by patients | Malaria cases and care seeking: household surveys |

(continued)
### Table 1 (continued)

| WHO/University of Edinburgh 2017 | WHO/London School of Hygiene and Tropical Medicine 2017 | Brock et al. 2017 | Luangpenapo et al. 2021 | SAFARI 2019-University of North Carolina | ESTEEM 2021-University of North Carolina | Renschler et al. 2015 |
|---------------------------------|---------------------------------|------------------|------------------------|----------------------------------------|----------------------------------------|---------------------|
| **Hospital care for severe case:** | Health Access Initiative SF prevalence: published literature | calculated based on mice and human experimental data for use of SP | SF Prevalence: published literature based on systematic review | Costs: ACT Watch reports, published literature | Costs: ACT Watch reports, published literature | Global Health Observatory Data Repository |
| **Main Outputs** | **Number of excess deaths occurring due to SF antibiotics** | **Averted:** Treatment failures | **Number of SP resistant infections** | **Total malaria cases** | **Duration of gametocyte carriage** | **Costs of inspections using 6 screening technologies** | **DALYs averted** | **5-year budget impact** | **Costs of screening** | **Averted:** SF treatments | Deaths caused by SF antimalarials |
| **Uncertainty** | **Alternative scenario:** 4 times the case fatality rate for those taking SF medicines | **Varied levels of SF prevalence at 1%, 5%, 10%** | **Univariate sensitivity analysis varied:** | | | | | | | | |
| **Main assumptions** | **Assumed global prevalence of SF medicines at 1%, 5%, and 10%; did not use individual country or regional data** | **Assumed SF antimalarials have diminished effectiveness based on API and being in a low or high transmission** | **Use of poor-quality SP was assumed as a good proxy for the use of all poor-quality medicines — using the same rate of gametocyte carriage** | **Assumed different prevalence scenarios for SF ACTs:** | **Assumed SF antimalarials have diminished effectiveness based on API:** | **Assumed use of SF amoxicillin results in twice the CFR** | **Assumed removal efforts of batches identified as SF are 100% effective** | **Assumed 80% of SF antimalarials increase the CFR of malaria.** | **Assumed SF antimalarials are only received by patients seeking care** | **(continued)**
| Region | Assumed Childhood Pneumonia | Assumed Only SP-Resistance Exists | Luangasanant et al. 2021 | SAFARI 2019 - University of North Carolina | ESTEEM 2021 - University of North Carolina | Renschler et al. 2015 |
|--------|-----------------------------|----------------------------------|--------------------------|------------------------------------------|-------------------------------------------|---------------------|
|        | region. Low transmission:   | Assumed that effectiveness is    | 85% genuine, 10%         | 75-85% API                              | pediatric pneumonia cases are prescribed with and use amoxicillin | care at private practices.
|        | Assumed that effectiveness is reduced by: | assumed half dose SP had higher gametocyte densities and longer infectivity | 10% substandard, 5% falsified | 50% for drugs with 50-75% API | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |
|        | 30% for drugs with 75-85% API | Assumed that half dose SP had higher gametocyte densities and longer infectivity | Assumed quality antimalarials replaced the failed batches for one month before returning to baseline level of SF | 100% (totally ineffective) for drugs with < 50% API | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |
|        | 60% for drugs with 50-75% API | Assumed that half dose SP had higher gametocyte densities and longer infectivity | Assumed quality antimalarials replaced the failed batches for one month before returning to baseline level of SF | Assumed children who are not cured may seek care again the next week | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |
|        | 100% (totally ineffective) for drugs with < 50% API | Assumed prevalence of SF antimalarials found regionally and globally reflects antimalarials in Kenya | Assumed one device per every 10 pharmacies in malaria endemic districts, varied in sensitivity analysis. | Assumed breakdown of API percentage represents national level | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |
|        | High transmission: Assumed that effectiveness is reduced by: | Assumed prevalence of SF antimalarials found regionally and globally reflects antimalarials in Kenya | Assumed one device per every 10 pharmacies in malaria endemic districts, varied in sensitivity analysis. | Assumed breakdown of API percentage represents national level | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |
|        | 25% for drugs with 75-85% API | Assumed prevalence of SF antimalarials found regionally and globally reflects antimalarials in Kenya | Assumed one device per every 10 pharmacies in malaria endemic districts, varied in sensitivity analysis. | Assumed breakdown of API percentage represents national level | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |
|        | 50% for drugs with 50-75% API | Assumed prevalence of SF antimalarials found regionally and globally reflects antimalarials in Kenya | Assumed one device per every 10 pharmacies in malaria endemic districts, varied in sensitivity analysis. | Assumed breakdown of API percentage represents national level | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |
|        | 100% (totally ineffective) for drugs with < 50% API | Assumed prevalence of SF antimalarials found regionally and globally reflects antimalarials in Kenya | Assumed one device per every 10 pharmacies in malaria endemic districts, varied in sensitivity analysis. | Assumed breakdown of API percentage represents national level | Assumed children who are not cured may seek care again the next week | Assumed patients cannot distinguish between SF and good-quality antimalarials (e.g., the prevalence of SF antimalarials at private facilities = the amount taken by patients) |

---

ACT = artemisinin-based combination therapy; AL = artemether-lumefantrine; ALRI = acute lower respiratory infections; API = active pharmaceutical ingredient; CFR = case fatality rate; DALY = disability-adjusted life year; DHS = demographic and health survey; DRC = the Democratic Republic of the Congo; ESTEEM = Examining Screening Technologies with Economic Evaluations for Medicines model; FDD = Food and Drug Department; MIS = malaria indicators survey; MICS = UNICEF Multiple Indicator Cluster Survey; SAFARI = Substandard and Falsified Antimalarial Research Impact model; SF = substandard and falsified; SP = sulfadoxine-pyrimethamine; WHO CHOICE = World Health Organization’s Choosing Interventions That Are Cost-Effective program.
WHO (2017), which provided approximate estimates of childhood deaths related to substandard or falsified antibiot-
ics used for treatment of pneumonia. Starting from global estimates of childhood pneumonia mortality derived from a
large burden of disease study, the authors calculated the number of pediatric pneumonia deaths attributable to
Poor-quality antimalarials were responsible for 122,350 pediatric malaria deaths annually across 39 sub-Saharan African countries.4

Two models examined the regional impact of substandard and falsified antimalarials in sub-Saharan Africa. The London
School of Hygiene and Tropical Medicine and the WHO (2017) developed a decision tree model to simulate the infec-
tion, care seeking, and outcomes of utilizing antimalarials at varying levels of quality.1 The model assumed a reduction in
antimalarial effectiveness based on the amount of the active pharmaceutical ingredient. The model considered that not all malaria cases will receive antimalarials due to care-seeking patterns and prescribing variations and that adherence also influences medicine effectiveness. The authors estimated that substandard and falsified antimalarials were responsible for 2.1% to 4.9% of total malaria deaths and $10.4 to $44.7 million in direct economic costs of care in sub-Saharan Africa, depending on estimates of malaria cases.1 Univariate sensitivity analysis found that the probability of progressing to severe malaria, probability of receiving further inpatient care after severe illness, and the cost of outpatient care had the greatest impact on results.

On the other hand, Ren schler et al. (2015) estimated that poor-quality antimalarials were responsible for 122,350 (interquartile range: 91,577–154,736) pediatric malaria deaths annually across 39 sub-Saharan African countries.4 The model used data on the prevalence of substandard and falsified antimalarials and estimates of under-five care seek-
ing for malaria from the literature. To account for uncertainty, this analysis used statistical modeling using Latin hypercube sampling to vary 79 input parameters, providing a range of possible outcomes. The case fatality rate used to estimate the impact of substandard and falsified antimalarials in each of the 10,000 runs directly affected the number of child deaths due to substandard or falsified antimalarials.

One agent-based model has been used to derive national estimates of the impact of poor-quality antimalarials. The Substandard and Falsified Antimalarial Research Impact (SAFARI) model has been applied in five countries to date: Benin, the Democratic Republic of the Congo, Nigeria, Uganda, and Zambia.5-9,15 The model incorporated demo-

graphic characteristics of a country population, which guided agents’ likelihood of being infected with malaria and care-seeking behaviors. Similar to the WHO 2017 malaria model, SAFARI assumed that antimalarial effectiveness was diminished based on the amount of API consumed. The model tracked substandard and falsified antimalarial treat-
ments consumed, severe cases and hospitalizations, deaths, disability, costs to patients and public facilities that provide care, productivity losses of caregiver time, and productivity losses due to premature death and life lived with disability. Using the SAFARI model, the impact of substan-
dard and falsified medicines was estimated ranging from 213 deaths or 8.1% of malaria deaths in Zambia to 12,300 deaths and $892 million in economic impact in Nigeria.8,9

The burden of poor-quality antimalarials weighed more heavily on poor and rural populations, furthering health inequities in Uganda.7

Modeling the cost-effectiveness of medicine quality screening technologies. Two country-level models have been developed to evaluate the cost-effectiveness of postmarket surveillance technologies to stop the circulation of substandard and falsified medicines. The Evaluating Screen-
ing Technologies for Economic Evaluation Model (ESTEEM) is an agent-based model used to simulate postmarket sur-
veillance strategies.10,16 Medicines were simulated as agents and classified as quality-assured, substandard, or falsified. The model simulated sampling, screening, confirmatory testing, and removal of failed medicines from the market. The model compared use of screening technologies that could lessen the need for confirmatory testing and speed up removal of substandard and falsified medicines from the market. ESTEEM estimated the number of substan-
dard and falsified treatments averted, deaths averted, costs of care saved, and productivity losses averted, and com-
pared them with added costs of screening and testing medicine quality. Results from a case study in Kenya showed that faster reductions in the prevalence of substandard and falsified antibiotics can have a substantial impact on health and economic outcomes.10

Another model examined the cost-effectiveness of six screening technologies to identify and remove poor-quality artemisinin combination therapies (ACTs) in Laos.11 Using a decision tree structure, they modeled the cost-effectiveness of each screening device compared with using visual inspection in hypothetical scenarios of high and low prevalence of poor-quality ACTs. All devices were cost-effective in the high prevalence scenario, with the near infrared spectromet-

Modeling the impact of medicine quality on anti-
microbial resistance. Only one model estimated the health impact of substandard and falsified medicines on drug resis-
tance. Brock et al. (2017) modeled the transmission dynam-
ics of resistant infections using mathematical models of humans and mosquitoes.12 The model incorporated patient care-seeking, medicine use, and prevalence of substandard and falsified medicines from the literature. Half doses of sul-
fadoxine/pyrimethamine (SP) were used to represent poor-
quality antimalarials, which resulted in longer duration of infectivity and higher malaria transmission. They found that given widespread SP resistance in Kenya, using poor-quality antimalarials increased the number of malaria cases overall (558.6% to 776.9% increase in cases) as well as the number of SP resistant infections. The authors simulated that using only quality-assured ACTs resulted in a 72.7% decrease in cases.12 One-way sensitivity analysis showed mosquito parameters (such as ratio of mosquitoes to humans, rate of mosquito maturity, probability of sporozoite transmission) to be especially important, as well as the rate of gametocyte clearance of infections treated with good quality ACTs.
DISCUSSION

We identified clear gaps in existing modeling literature on substandard and falsified medicines. Although the impact of substandard and falsified products is relevant for most classes of medicines, only antibiotics and antimalarials were represented in the modeling literature. A recent meta-analysis found that uterotonic s, antihypertensives, and antiflammatories, among others, failed quality tests at high rates, but estimates of the burden caused by those medicines are not yet available. In addition, we found that only countries in sub-Saharan Africa or the overall region without country-specific breakdowns were modeled. To tailor specific interventions, decision-makers require greater evidence relevant to various medicines and populations at risk.

There were commonalities across models, especially in the flow and types of inputs used. Each model began with the overall burden of disease, using either the number of cases or deaths for the country, region, or world or disease incidence. Care-seeking options were always considered, which influenced the type of medicines consumed and their quality. Finally, the outcomes depended on the quality of medicine, where simulated ineffectiveness resulted in more severe disease, further treatment, longer infectivity, or a higher probability of death. In models that included costs, we saw that the economic burden of substandard and falsified medicines fell on patients and the health care system to pay for additional costs of care, and also on society in terms of productivity losses incurred.

Two key assumptions made in each of these models indicate areas for future research and stakeholder collaboration. First, the true prevalence of substandard and falsified medicines is not known for the scope that these models assess, and literature to inform this parameter is limited. Although reports on medicine quality are increasing, the data are not always generalizable across populations. Strengthening medicines regulatory authorities to be able to regularly collect and share medicine quality data is one way to provide stronger evidence and engage stakeholders in impact modeling. The second assumption that warrants further consideration is the clinical implications of using substandard and falsified medicines. This parameter will likely vary for the medicine type as well as the quality level (substandard, falsified, or quality-assured) and has rarely been studied. The models must make assumptions about substandard and falsified medicines leading to retreatment or an increased probability of death. Gaining validation from experts, including pharmacologists with expertise in pharmacokinetics and pharmacodynamics, on the clinical burden of using substandard and falsified medicines is vital for model precision. The uncertainty in these assumptions underscores the importance of rigorous sensitivity analysis in modeling the impact of substandard and falsified medicines. Despite such uncertainty, the scale of the problem and the need for evidence by decision-makers warrant further use and development of models in this area.

An understanding of the limitations of these models is important as decision-makers look to use such evidence to inform investments towards improving medicine quality. One of the greatest limitations is the lack of evidence on the costs and effectiveness of interventions to improve medicine quality because these models focus primarily on the burden of substandard and falsified medicines rather than demonstrate the value of specific interventions. Current models do not incorporate a detailed simulation of the supply chain to identify bottlenecks or demonstrate the impact of specific policies, regulations, or postmarket surveillance measures. Greater evidence is needed across medicine quality interventions throughout the medicine supply chain to model their return on investment. Another significant limitation is the generalizability of model findings across settings and the level of heterogeneity incorporated in models to examine the impact on subpopulations. Although existing evidence offers a helpful guide, careful deliberations may be needed to interpret model findings in different settings or for specific populations.

This review is limited by search parameters and databases screened. However, we believe we have included the most relevant models that are representative of the goals and methods used in modeling the impact of substandard and falsified medicines. Although the characteristics of each model are not listed in exhaustive detail, we summarized what we found to be the most important mechanisms, data, and modeling techniques. This review identified areas for future research to better estimate the health and economic impacts of substandard and falsified medicines and make a stronger case for solutions.

CONCLUSION

Every person has the right to expect that a medical product works as intended. Medicine quality assurance is essential for countries to reach Universal Health Coverage (UHC) goals. Efforts to ensure medicine quality is even more critical during the COVID-19 pandemic as regulatory and supply chain systems have been disrupted. Simulation models can provide estimates of the impact of substandard and falsified medicines that NMRAs and other stakeholders can use to advocate for needed resources to strengthen medicine quality assurance systems. To ensure that these modeled estimates are actionable, modeling efforts should be extended to include more medicines and provide country- and population-specific data.

Received October 27, 2021. Accepted for publication January 21, 2022.

Acknowledgments: We thank core partners at the University of Washington (Andrew Stergachis, Josh Carlson, and Sabra Zaraa) and Harvard Medical School (Dennis Ross-Degnan) for their constructive comments, as well as contributions from the U.S. Agency for International Development and the PQM+ program (Leslie Rider-Araki and Poonam Kakani) in guiding this project.

Financial support: This work was made possible by the generous support of the American people through the U.S. Agency for International Development (USAID) through the Promoting the Quality of Medicines Plus (PQM+) Program via Cooperative Agreement number 7200AA19CA00025. The views and opinions expressed in this paper are those of the authors and not necessarily the views and opinions of USAID or the U.S. government.

Authors’ addresses: Sachiko Ozawa and Colleen R. Higgins, University of North Carolina at Chapel Hill, Chapel Hill, NC, E-mails: ozawa@unc.edu and collhigg@live.unc.edu. Jude I. Nwokike and Souly Phanouvong, University of North Carolina at Chapel Hill, Chapel Hill, NC, E-mails: jin@usp.org and sxp@usp.org.
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. World Health Organization, 2017. A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products. Geneva, Switzerland: WHO.

2. Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, Henning JE, 2018. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open 1: e181662–e181662.

3. World Health Organization, 2017. Definitions of Substandard and Falsified (SF) Medical Products. Geneva, Switzerland: WHO. Available at: https://www.who.int/medicines/regulation/ssfcd/definitions/en/. Accessed April 9, 2021.

4. Renschler JP, Walters KM, Newton PN, Laxminarayan R, 2015. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa. Am J Trop Med Hyg 92: 119–126.

5. Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P, 2019. Development of an agent-based model to assess the impact of substandard and falsified antimalarials: Uganda case study. Malar J 18: 5.

6. Ozawa S, Haynie DG, Bessias S, Laing SK, Ngamasana EL, Yemeke TT, Evans DR, 2019. Modeling the economic impact of substandard and falsified antimalarials in the Democratic Republic of the Congo. Am J Trop Med Hyg 100: 1149–1157.

7. Evans DR, Higgins CR, Laing SK, Awor P, Ozawa S, 2019. Poor-quality antimalarials further health inequities in Uganda. Health Policy Plan 34: ii36–ii47.

8. Beargie SM, Higgins CR, Evans DR, Laing SK, Erim D, Ozawa S, 2019. The economic impact of substandard and falsified antimalarial medications in Nigeria. PLoS One 14: e0217910–e0217910.

9. Jackson KD, Higgins CR, Laing SK, Mwila C, Kobayashi T, Ippolito MM, Sylvia S, Ozawa S, 2020. Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model. BMC Public Health 20: 1083.

10. Chen H-H, Higgins C, Laing SK, Bliese SL, Lieberman M, Ozawa S, 2021. Cost savings of paper analytical devices (PADs) to detect substandard and falsified antibiotics: Kenya case study. Medicine Access Point Care 5: 2399202620983030.

11. Luangasanatip N, Khonputsa P, Calliet C, Vickers S, Zambrzycki S, Fernández FM, Newton PN, Lubell Y, 2021. Implementation of field detection devices for antimalarial quality screening in Lao PDR-A cost-effectiveness analysis. PLoS Negl Trop Dis 15: e0009539–e0009539.

12. Brock AR, Ross Jv, Greenhalgh S, Durham DP, Galvani A, Parikh S, Esterman A, 2017. Modelling the impact of antimalarial quality on the transmission of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Infect Dis Model 2: 161–187.

13. Liu L et al., 2016. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the sustainable development goals. Lancet 388: 3027–3035.

14. Nair H et al., 2013. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 381: 1380–1390.

15. Bui V, Higgins C, Laing S, Ozawa S, 2021. Assessing the impact of substandard and falsified antimalarials in Benin. Am J Trop Med Hyg Nov 8: tpmd210450.

16. Higgins C, Kobia B, Ozawa S, 2022. Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: a Kenya case study. Working paper. Chapel Hill, NC: University of North Carolina at Chapel Hill.

17. Ozawa S, Chen H, Lee Y, Higgins CR, Yemeke TT, 2022. Characterizing medicine quality by active pharmaceutical ingredient levels: a systematic review and meta-analysis across low- and middle-income countries. Am J Trop Med Hyg 21: 1123.

18. Newton PN et al., 2019. Global access to quality-assured medical products: the Oxford Statement and call to action. Lancet Glob Health 7: e1609–e1611.

19. Ozawa SP, Yemeke T, Higgins C, Pribulda VS, Hajjou, M, Evans L III, Nwokike JI, 2019. Integrating Medicines Quality Assurance into Universal Health Coverage Programming: A Path to Reducing Waste and Increasing Access to Essential Medical Products. Available at: https://www.usp-pqm.org/sites/default/files/field/image/pqm-uhc-white-paper.pdf.

20. Ozawa S, Higgins CR, Yemeke TT, Nwokike JI, Evans L, Hajjou M, Pribulda VS, 2020. Importance of medicine quality in achieving universal health coverage. PLoS One 15: e0232966.

21. Newton PN, Bond KC, 2020. COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. Lancet Glob Health 8: e754–e755.